首頁 > 市場調查報告書 > 製藥

孤兒藥

拉丁美洲法布裡病市場：按治療類型（酵素替代療法,伴侶療法,底物還原療法）,給藥途徑,分銷渠道,國家-市場規模,份額,前景和機會分析2022-2030

市場調查報告書

商品編碼

1149800

拉丁美洲法布裡病市場：按治療類型（酵素替代療法,伴侶療法,底物還原療法）,給藥途徑,分銷渠道,國家-市場規模,份額,前景和機會分析2022-2030

LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy Chaperon Therapy, Substrate Reduction Therapy ), by Route of Administration, by Distribution Channel, and by Country - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年09月26日 | 出版商:

Coherent Market Insights | 英文 245 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

法布裡病是一種遺傳性疾病，由體內細胞中堆積的三糖神經□胺（一種脂肪）引起。法布裡病的症狀可以出現在身體的任何部位，包括出汗能力下降、手腳酸痛和消化問題。脫氧核糖核酸序列分析和酵素分析等測試用於診斷法布裡病。

法布裡病的治療方法包括靜脈內酵素替代療法和口服伴侶療法，這可能還需要改變生活方式和進行預防性藥物治療。他們可能還會向您推薦止痛藥、胃病藥、治療心律失常等心臟問題的血液稀釋劑、降壓藥和保護腎臟的藥。如果法布裡病導致嚴重的腎臟損害，則可能需要透析或腎移植治療。

市場動態

有關法布裡病的結果和知識的研究有望推動拉美法布裡病市場的增長。例如，根據 Orphanet Journal of Rare Diseases 於 2022 年 6 月 20 日發布的數據，一組研究人員將更好地了解法布裡病，包括了解見解、結果，以及對其發展、治療效果和治療效果的了解更多。我們進行了一項為期 20 年的 Fabry 績效研究，重點是深化。

監管機構更新了用於治療法布裡病的藥物開髮指南，預計將推動拉丁美洲法布裡病市場的增長。例如，2019 年 8 月，美國食品和藥物管理局宣布提供工業界開發治療法布裡病藥物的指南草案。本指南草案描述了 FDA 目前關於資格標準、研究設計注意事項和療效終點的建議，這些建議將用於治療法布裡病的研究藥物的臨床開發計劃。

這項研究的主要特點

本報告對拉丁美洲法布裡病市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模（百萬美元）和復合年增長率 (CAGR%)
它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
它還提供了有關市場驅動因素和推動因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
根據公司概況、業績、產品組合、市場佔有率、分銷戰略、關鍵發展、戰略和未來計劃等參數對拉丁美洲法布裡疾病市場的主要參與者進行了介紹。
本次調查涵蓋的主要公司包括 Amicus Therapeutics, Inc.、Sanofi-Aventis U.S. LLC、GlaxoSmithKline plc、Mendelics、Takeda Pharmaceuticals U.S.A., Inc、Teva pharmaceutical Industries Ltd、Pfizer Inc.、Novartis AG、Moderna Therapeutics Inc 和Resverlogix。
這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
LATAM Fabry Disease 市場報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以通過用於分析 LATAM Fabry 疾病市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

報告內容
- 市場定義和範圍
執行摘要
- 市場細分：按治療類型
- 按給藥途徑細分的市場
- 市場細分：按分銷渠道
- 按國家/地區劃分的市場細分
連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

市場動態
- 司機
- 約束因素
- 市場機會
影響分析
市場趨勢
主要發展狀況
最近的產品發布/批准
市場參與者採用的主要策略
害蟲分析
流行病學
併購

第 4 章 LATAM Fabry 市場：冠狀病毒 (COVID-19) 大流行的影響

經濟影響
對供應鏈的影響
政府舉措

第 5 章拉丁美洲法布裡病市場：按治療類型分類，2017-2030

酵素替代療法
2017-2030 年市場規模、預測、同比增長率
伴侶療法
2017-2030 年市場規模、預測、同比增長率
酵素替代療法
2017-2030 年市場規模和預測，同比增長率

第 6 章拉丁美洲法布裡病市場：按給藥途徑，2017-2030

口服劑
腸外給藥

第 7 章。拉丁美洲法布裡病市場：分銷渠道，2017-2030

醫院藥房
在線藥店
零售藥房

第 8 章拉丁美洲法布裡病市場：國家，2017-2030

拉丁美洲
2017-2030 年按治療類型劃分的市場規模和預測
市場規模和預測：按給藥途徑，2017-2030 年
市場規模和預測：按分銷渠道分類，2017-2030 年
按治療類型劃分的市場規模和預測：2017-2030 年
2017-2030 年按給藥途徑劃分的市場規模和預測
2017-2030 年各分銷渠道的市場規模和預測
2017 年至 2030 年按治療類型劃分的市場規模和預測
2017-2030 年按給藥途徑劃分的市場規模和預測
2017-2030 年各分銷渠道的市場規模和預測
2017 年至 2030 年按治療類型劃分的市場規模和預測
2017-2030 年按給藥途徑劃分的市場規模和預測
市場規模和預測：按分銷渠道分類，2017-2030 年

第9章競爭格局

熱圖分析
市場份額分析
- Amicus Therapeutics, Inc.
- Sanofi-Aventis U.S. LLC
- GlaxoSmithKline plc
- Mendelics
- Takeda Pharmaceuticals U.S.A., Inc.
- Teva pharmaceutical Industries Ltd
- Pfizer Inc.
- Novartis AG
- Moderna Therapeutics Inc
- Resverlogix

第 10 章

參考資料
調查方法介紹

簡介目錄

Product Code: CMI5249

Fabry disease is an inherited disorder which is caused by accumulation for globotriaosylceramide, a type of fat, in the body's cells. Fabry disease symptoms affect body parts which include a decreased ability to sweat, events of pain in hands and feet, difficulties with the gastrointestinal system, etc. Diagnosis for fabry disease includes test such as Deoxyribonucleic acid sequence analysis, enzyme assay analysis, etc.

Treatment for fabry disease includes intravenously administered enzyme replacement therapy or oral chaperone therapy, along with this it may also need lifestyle modifications and prophylactic medications. Sometimes doctors also refer drugs to relieve pain, medicine for stomach problems, blood thinners or other drugs for an irregular heartbeat or other heart problems, blood pressure medicine, which also helps to protect kidneys. If fabry disease has caused serious kidney damage, dialysis or a kidney transplant is needed for treatment.

Market Dynamics

Survey regarding achievements or learning about fabry disease, is expected to drive growth of the LATAM fabry disease market. For instance, according to data published on June 20, 2022, by Orphanet Journal of Rare Diseases, a team of researchers had done 20 years of Fabry Outcome Survey that focused to broaden the understanding of fabry disease such as to know about the insights, achievements, and learning more about the development of fabry disease, effects of treatment, etc. according to same Route of Administration population suffering from fabry disease has reported cardiovascular problem and it was more common type of problem reported in male and female in with fabry disease in Latin America.

Updated guidelines by regulatory bodies for the development of drugs used in the treatment of fabry disease is expected to drive the LATAM fabry disease market growth. For instance, in August, 2019, the U.S. Food and Drug Administration announced the availability the draft guidance for the industries, to develop drugs for the treatment of fabry disease. This draft guidance describes the FDA's current recommendations regarding eligibility criteria, trial design considerations, and efficacy endpoints to be used in clinical development programs of investigational drugs to treat fabry disease.

Key features of the study:

This report provides in-depth analysis of the LATAM fabry disease market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the LATAM fabry disease market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amicus Therapeutics, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Mendelics, Takeda Pharmaceuticals U.S.A., Inc, Teva pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, Moderna Therapeutics Inc, and Resverlogix.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The LATAM fabry disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the LATAM fabry disease market

Detailed Segmentation:

LATAM Fabry Disease Market, By Therapy Type:
- Enzyme Replacement Therapy
  - Agalsidase Beta (Fabrazyme)
  - Agalsidase Alfa (Replagal)
  - Pegunigalsidase Alfa (PRX-102, Phase III)
- Chaperon Therapy
  - Migalastat (Galafold Phase III)
- Substrate Reduction Therapy
  - Lucerastat (Phase III)
  - Venglustat (Phase III)
LATAM Fabry Disease Market, By Route of Administration:
- Oral
- Parental
LATAM fabry disease market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
LATAM Fabry Disease Market, By Country:
- Brazil
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Mexico
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Argentina
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Rest of Latin America
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
Company Profiles
- Amicus Therapeutics, Inc. *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Sanofi-Aventis U.S. LLC
- GlaxoSmithKline plc
- Mendelics
- Takeda Pharmaceuticals U.S.A., Inc.
- Teva pharmaceutical Industries Ltd
- Pfizer Inc.,
- Novartis AG
- Moderna Therapeutics Inc
- Resverlogix

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Recent Product Launch/Approval
Key Strategies Adopted by Market Players
PEST Analysis
Epidemiology
Mergers and Acquisitions

4. LATAM Fabry Disease Market - Impact of Coronavirus (COVID-19) Pandemic

Economic Impact
Impact on Supply Chain
Government Initiatives

5. LATAM Fabry Disease Market, By Therapy Type, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Enzyme Replacement Therapy
- Agalsidase Beta (Fabrazyme)
- Agalsidase Alfa (Replagal)
- Pegunigalsidase Alfa (PRX-102, Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Chaperon Therapy
- Migalastat (Galafold Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Enzyme Replacement Therapy
- Lucerastat (Phase III)
- Venglustat (Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. LATAM Fabry Disease Market, By Route of Administration, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. LATAM Fabry Disease Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. LATAM Fabry Disease Market, By Country, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Country, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Country, 2017-2030
Latin America
- Brazil
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Mexico
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Argentina
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Rest of Latin America
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)